SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Vertex Pharmaceuticals (VRTX)
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
1169 64 0 VRTX
Emcee:  David Lieberman Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1019<i>Vertex to start Phase 3 trial of hepatitis drug PR and also comments bytnsaf-8/19/2008
1018<i>Any feel yet for which drug gets to market first?</i> It’s goingDewDiligence_on_SI-8/4/2008
1017>> I’ve upgraded Boceprevir to equal ranking with Telaprevir. Any feel yeIRWIN JAMES FRANKEL-8/4/2008
1016HCV: Most Likely to Succeed (IMHO) <i>[Based on today’s news, I’ve upgradDewDiligence_on_SI-8/4/2008
1015<i>Thanks, idos. I've copied the text here for when the Yahoo link extnsaf-8/1/2008
1014Update from C208 trial: data supports 2xday dosing for telaprevir biz.yahoo.comidos-8/1/2008
1013Vertex Investors Balk at New Study Plans - Adam Feuerstein 06/24/08 - 09:27 AM Etnsaf-6/24/2008
1012Derek Lowe and others comment on recent research on aurora kinase inhibitors: ptuck-6/23/2008
1011My take on today’s PR: siliconinvestor.comDewDiligence_on_SI-6/9/2008
1010<i>Adam Feuerstein's take on the results Bold emphasis added</i>tnsaf-6/9/2008
1009Apparently Cowen’s Rachael McMinn was right with her first assumption: <b>idos-6/9/2008
1008She is assuming better than expected SVR rates in 12+12 arm of PROVE 3 and Phaseidos-6/7/2008
1007<i>I think Cowen’s Rachael McMinn is assuming that having great data in trDewDiligence_on_SI-6/6/2008
1006I think Cowen’s Rachael McMinn is assuming that having great data in treatment-idos-6/6/2008
1005siliconinvestor.comDewDiligence_on_SI-6/5/2008
1004<b>Vertex rises on analyst look at telaprevir data</b> biz.yahoo.coidos-6/5/2008
1003Vertex Pharmaceuticals Sells HIV Product Royalty Stream for $160 Million Tuesdaytnsaf-6/3/2008
1002And VRTX took the hit immediately.tom pope-5/21/2008
1001Bcoceprevir is breathing down Telaprevir's neck - SGP announced the initiatiidos-5/21/2008
1000I don't necessarily think so. But the stock probably takes a hit anyway, becrkrw-5/13/2008
999Is this a consequential revelation re PROVE-3? siliconinvestor.comDewDiligence_on_SI-5/13/2008
998<i>I re-read that Feuerstein piece and took it to mean that TVR was roughlDewDiligence_on_SI-4/28/2008
997I re-read that Feuerstein piece and took it to mean that TVR was roughly 10 percCasaubon-4/28/2008
996Telaprevir, Boceprevir, and Feuerstein’s gaffe: siliconinvestor.comDewDiligence_on_SI-4/28/2008
995Merrill. I sold this a.m. as it failed to hold the earlier gains. <i>Bocetom pope-4/28/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News